Johnson & Johnson annual operating income
2009
2010
2011
2012
2013
2014
2022
2023
2024
2025
Johnson & Johnson Operating Income Growth & History (JNJ)
Johnson & Johnson's operating income was $25.60B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $25.60B | $4.35B | +20.46% |
| 2024 | 2024-12-29 | $21.25B | −$760.0M | −3.45% |
| 2023 | 2023-12-31 | $22.01B | $996.0M | +4.74% |
| 2022 | 2023-01-01 | $21.01B | — | — |
| 2014 | 2014-12-28 | $21.59B | $5.18B | +31.55% |
| 2013 | 2013-12-29 | $16.41B | $1.46B | +9.74% |
| 2012 | 2012-12-30 | $14.96B | $1.19B | +8.65% |
| 2011 | 2012-01-01 | $13.77B | −$3.94B | −22.23% |
| 2010 | 2011-01-02 | $17.70B | $1.12B | +6.74% |
| 2009 | 2010-01-03 | $16.58B | — | — |
Johnson & Johnson quarterly operating income
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $7.17B | $464.0M | +6.92% |
| Q1 2026 | 2026-03-29 | $6.39B | — | — |
| Q4 2025 | 2025-12-28 | $5.59B | — | — |
| Q3 2025 | 2025-09-28 | $7.10B | — | — |
| Q2 2025 | 2025-06-29 | $6.71B | — | — |
| Q1 2015 | 2015-03-29 | $5.83B | $176.0M | +3.11% |
| Q4 2014 | 2014-12-28 | $3.01B | −$27.0M | −0.89% |
| Q3 2014 | 2014-09-28 | $7.05B | $3.18B | +82.15% |
| Q2 2014 | 2014-06-29 | $5.88B | $855.0M | +17.03% |
| Q1 2014 | 2014-03-30 | $5.65B | $1.17B | +26.08% |
| Q4 2013 | 2013-12-29 | $3.04B | −$305.0M | −9.12% |
| Q3 2013 | 2013-09-29 | $3.87B | $47.0M | +1.23% |
| Q2 2013 | 2013-06-30 | $5.02B | $2.36B | +88.93% |
| Q1 2013 | 2013-03-31 | $4.48B | −$648.0M | −12.63% |
| Q4 2012 | 2012-12-30 | $3.34B | $2.49B | +292.37% |
| Q3 2012 | 2012-09-30 | $3.83B | −$824.0M | −17.72% |
| Q2 2012 | 2012-07-01 | $2.66B | −$881.0M | −24.90% |
| Q1 2012 | 2012-04-01 | $5.13B | $404.0M | +8.55% |
| Q4 2011 | 2012-01-01 | $852.0M | — | — |
| Q3 2011 | 2011-10-02 | $4.65B | $288.0M | +6.60% |
| Q2 2011 | 2011-07-03 | $3.54B | −$840.0M | −19.19% |
| Q1 2011 | 2011-04-03 | $4.73B | — | — |
| Q3 2010 | 2010-10-03 | $4.36B | — | — |
| Q2 2010 | 2010-07-04 | $4.38B | — | — |
Johnson & Johnson operating income trends
Between the periods ended 2010-01-03 and 2025-12-28, Johnson & Johnson's operating income increased from $16.58B to $25.60B, a change of $9.01B. The latest reported quarter, Q2 2026, shows $7.17B.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
